How Does This Drug Distributor Operate?
Cencora is a health-care services company that sits in the middle of the drug supply chain. It distributes pharmaceuticals and provides related support services that help manufacturers and providers move products efficiently. The business is built around high-volume, repeat purchasing and logistics execution. At roughly USD 60.8 billion in market value, it’s a large, scaled operator in its niche.
Are Thin Margins Limiting Profit Growth?
FundamentalsFor the year ended September 30, 2025 (reported in USD), revenue was USD 321.3 billion, with EBIT of USD 2.63 billion and net income of USD 1.57 billion. Revenue grew 9.3% versus the prior year, while profitability stayed characteristically thin on a margin basis, with a 3.63% gross margin, 0.82% operating margin, and 0.50% net profit margin on a trailing basis.
Reinvestment and cash conversion show up in the gap between depreciation and capital spending: D&A was USD 501.3 million against capex of USD 668.0 million. Using the provided cash-flow proxy definition, the business generated about USD 1.77 billion. The balance sheet carried USD 4.36 billion of cash alongside USD 7.66 billion of total debt.
Is The Market Overpaying For Reinvestment?
DCF / MultiplesAt USD 312.39 per share, the stock trades well below the discounted cash-flow outcomes implied by the valuation work, even under a weaker scenario. That pricing contrast is paired with a 37.39 trailing P/E and 18.02 EV/EBITDA, multiples that indicate the market is paying for durable earnings power and continued compounding rather than just today’s spread-based margins.
High Expectations Require Precision
TakeawayThe valuation already assumes reinvestment keeps compounding efficiently. That requires sales growth to persist without margin giveback. Cash generation needs to stay ahead of ongoing capital spending. If growth slows, the current multiple becomes harder to justify. Thin operating margins leave less buffer for execution misses.